TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04882761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Comparative

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Comparative
Study: NCT00672386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Counseling
Description: Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
Study: NCT03961386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FallsTalk-C
Description: The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FallsTalk
Description: The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FallsTalk
Description: The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
Study: NCT03026140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29
Study: NCT02958280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit&Sober App
Description: Fit\&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice
Description: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
Study: NCT03118141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blastocyst morphologic score
Description: Blastocysts will be scored by Gardner morphologic criteria.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blastocyst morphologic score
Description: Blastocysts will be scored by Gardner morphologic criteria.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blastocyst biopsy and sequencing
Description: Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freeze-all and single thawed blastocyst transfer
Description: All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freeze-all and single thawed blastocyst transfer
Description: All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
Study: NCT01612637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and lifestyle advice
Description: Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle advice
Description: Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
Study: NCT04446845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
Description: Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Study: NCT00596024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lutein/zeaxanthin
Description: daily supplementation of lutein and zeaxanthin at dose of 12 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
Study: NCT03646903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Modification
Description: Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
Study: NCT04446845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Stimulation (Elonva+rFSH) in follicular phase
Description: From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Study: NCT03061201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-525 (PF-07055480)
Description: Single dose of investigational product SB-525 (PF-07055480)
Study: NCT01191775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Description: Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
Study: NCT02027662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osvaren Granules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osvaren film-coated tablets
Study: NCT03156179

Intervention type: DIAGNOSTIC_TEST
Intervention: calcium isotope analysis
Description: A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample \[(42Ca/48Ca) / (44Ca/48Ca)\] is the fractional calcium absorption.
Study: NCT00536224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full counseling
Description: The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal counseling
Description: Patients assigned to the minimal counseling intervention received brief counseling (\<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal.
Study: NCT00347919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034) 400 mg
Description: 400 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016) 1500 mg
Description: 1500 mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016) 1500 mg
Description: 1500 mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016) 1000 mg
Description: 1000 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034) 800 mg
Description: 800 mg administered orally once daily
Study: NCT01968707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep Hi-Lite Orange
Description: Apply topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Apply topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep Tint 10.5-mL
Description: Apply topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep Tint 26-mL
Description: Apply topically
Study: NCT04424212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group CoronaCope
Description: Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
Study: NCT00765895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline Hydrochloride
Description: Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for nortriptyline)
Description: Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
Study: NCT04842188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF with aPDT
Description: surgical open flap debridement followed by L-PRF with aPDT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: surgical open flap debridement followed by L-PRF alone
Study: NCT04506905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
Study: NCT01636830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush type
Description: Evaluate the use of toothbrushes with bristles soft and medium

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush type
Description: Evaluate the use of toothbrushes with bristles soft and medium
Study: NCT02919397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable technology
Description: Buddi wearable technology will record activity levels, participants will access activity data through smartphone application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable technology
Description: Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
Study: NCT04506905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
Study: NCT02919397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Programme educational material
Description: Educational material accessed through smartphone application
Study: NCT04506905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of dose-matched placebo to MK-8189 according to randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of dose-matched placebo to MK-8189 according to randomization
Study: NCT04768127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early aftercare
Description: This group begins the aftercare program immediately after their bariatric surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mid-term to late aftercare
Description: This group begins the aftercare program 18 months post surgery.
Study: NCT03196427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion